Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 31, 2019- FDA feedback from End‑of‑Phase 1 meeting indicates IDEAYA's proposed single-arm Phase 2 clinical trial may be adequate to support an NDA seeking Accelerated Approval for IDE196 monotherapy in metastatic uveal melanoma (MUM)
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using...
-
Oct 25, 2019
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using...
-
Oct 8, 2019
IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announces it has dosed its first...
-
Aug 12, 2019
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using...
-
Jul 11, 2019
IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announces initiation of its Phase 1/2...
-
Jul 9, 2019
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced the promotions...
-
May 28, 2019
IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the closing of its initial public offering of 5,750,000 shares of common stock at a public offering price of $10.00 per share. The gross...
-
May 22, 2019
IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $10.00 per share, before...
-
May 8, 2019
IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced that the U.S. Food and Drug...
-
Mar 29, 2019
IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced that Novartis will present a...
